SCHEMBL2064402

SCHEMBL2064402

COC(=O)Cc1c(Cl)ncnc1NCc1ccc(OC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
ALDH1A1 P00352 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HTT P42858 1/20 0.53
EGFR P00533 4/20 0.51
POLB P06746 2/20 0.51
NR2F2 P24468 1/20 0.51
AURKA O14965 2/20 0.51
RPS6KB1 P23443 2/20 0.51
PDE5A O76074 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
VNN1 O95497 2/20 0.47
THRB P10828 1/20 0.47
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CDK1 P06493 3/20 0.46
CCNB2 O95067 2/20 0.46
CCNB1 P14635 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10219832 0.88 AURKA (0.47) LMNASMN1; SMN2HTTEGFRNR2F2
SCHEMBL28899299 0.84 CCNE2 (0.50) LMNAALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL2063881 0.83 CYP1A2 (0.53) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL15561113 0.82 LMNA (0.56) LMNAALDH1A1SMN1; SMN2HTTEGFR
SCHEMBL16781105 0.82 LMNA (0.58) LMNAALDH1A1SMN1; SMN2HTTEGFR
SCHEMBL20061415 0.81 HTT (0.54) LMNAALDH1A1SMN1; SMN2HTTEGFR
SCHEMBL20061544 0.81 AURKA (0.59) LMNAALDH1A1SMN1; SMN2HTTEGFR
SCHEMBL19320545 0.80 LMNA (0.56) LMNAALDH1A1SMN1; SMN2HTTEGFR
SCHEMBL20061442 0.80 HTT (0.52) LMNAALDH1A1SMN1; SMN2HTTEGFR
SCHEMBL20081398 0.79 HTT (0.54) LMNAALDH1A1SMN1; SMN2HTTEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216302-B Akt and p70 s6 kinase inhibitors LILLY CO ELI 2013-08-21 CN disclosed
EP-2358710-B1 AKT AND P70 S6 KINASE INHIBITORS LILLY CO ELI (US) 2012-08-15 EP disclosed
US-8148387-B2 AKT and P70 S6 kinase inhibitors ELI LILLY AND COMPANY (US) 2012-04-03 US disclosed
CN-102216302-A Akt and p70 s6 kinase inhibitors LILLY CO ELI 2011-10-12 CN disclosed
EP-2358710-A1 AKT AND P70 S6 KINASE INHIBITORS Eli Lilly and Company (US) 2011-08-24 EP disclosed
WO-2010056563-A1 AKT AND P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2010-05-20 WO disclosed
US-20100120801-A1 AKT AND P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120801-A1 AKT AND P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, MTOR LMNA 4229/4885ALDH1A1 4352/4885SMN1; SMN2 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.